This study also showed that two pathways, ACE/ACE2 and IL-17, were found to be potential synergistic regulatory targets for COVID-19 and IBD, and that for the use of IBD drugs and vaccines during a COVID-19 pandemic the benefits outweigh the risks, and that individualized clinical monitoring of IBD patients would be the best therapeutic strategy for effective disease control [71]. This evidence concerns the gene IL17A and inflammatory bowel disease.